Currently, ETA antagonists are being evaluated for their antitumor efficacy in a variety of preclinical and clinical trials for cancers such as melanoma, glioblastoma, prostate cancer, lung cancer, and colorectal cancer, which are closely related to the expression and activity of ETA14. Here, EDNRA is linked to prostate carcinoma.